Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review

Kaley, Thomas; Barani, Igor J.; Chamberlain, Marc C.; McDermott, Michael; Panageas, Katherine S.; Raizer, Jeffrey J.; Rogers, Leland; Schiff, David; Vogelbaum, Michael A.; Weber, Damien Charles; Wen, Patrick Y.

doi:10.1093/neuonc/not330

Cited by 214 publications

(177 citation statements)

References 47 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…Recurrence rates are substantially higher if only subtotal surgical removal could be achieved; in these cases a course of adjuvant radiation therapy to lower probability of recurrence or, alternatively, close imaging follow-up to pick up recurrence early should be considered (20). An ideal imaging modality to guide meningioma management should therefore be as accurate as possible to delineate tumor from tumor-free tissue in order to achieve the maximal safe resection and to detect remaining or recurrent tumor tissue as reliably as possible.…”

Section: Discussionmentioning

confidence: 99%

Increased ⁶⁸Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue

Rachinger¹,

Stoecklein²,

Terpolilli³

et al. 2015

J Nucl Med

153

145

View full text Add to dashboard Cite

Meningiomas are known to express somatostatin receptor 2 (SSTR2). PET using the SSTR2 analog 68 Ga-DOTATATE has recently been introduced for imaging of meningiomas. However, a systematic correlation between 68 Ga-DOTATATE uptake, SSTR2 expression, and histology (including tumor-free scar tissue) is still lacking. For elucidation, we conducted this prospective study. Methods: Twenty-one adult patients with primary (n 5 12) or recurrent (n 5 9) meningiomas were prospectively enrolled. Preoperative MR imaging and 68 Ga-DOTATATE PET scans were fused and used for a spatially precise neuronavigated tissue-sampling procedure during tumor resection. Histopathologic diagnosis included immunohistochemical determination of SSTR2 expression. At each individual sampling site, the maximum standardized uptake value (SUV max ) of 68 Ga-DOTATATE was correlated with MR imaging findings, histology, and semiquantitative SSTR2 expression. Results: One hundred fifteen samples (81 tumor, 34 tumor-free) were obtained. There was a significant positive correlation between SUV max and SSTR2 expression. Receiver-operating characteristic analysis revealed a threshold of 2.3 for SUV max to discriminate between tumor and nontumoral tissue. Regarding the detection of tumor tissue, PET imaging showed a higher sensitivity (90% vs. 79%; P 5 0.049), with specificity and positive predictive values similar to MR imaging, for both de novo and recurrent tumors. Conclusion: 68 Ga-DOTATATE uptake correlates with SSTR2 expression and offers high diagnostic accuracy to delineate meningioma from tumor-free tissue even in recurrent tumors after previous therapy. Our findings substantiate an important role for 68 Ga-DOTATATE PET in meningioma management.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased ⁶⁸Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue

Rachinger¹,

Stoecklein²,

Terpolilli³

et al. 2015

J Nucl Med

153

145

View full text Add to dashboard Cite

show abstract

“…As a whole, chemotherapy for AMs has had limited success. In a recent review of surgery-and radiation-refractory AMs and MMs treated with medical therapies, the weighted average PFS at 6 months was 26% (95% CI 19.3%-32.7%); 38 stratification by Grade II versus III was not available because most studies pooled AMs and MMs together. Pa-tients with these refractory tumors typically have a median overall survival of only 6-33 months.…”

Section: Chemotherapymentioning

confidence: 99%

“…Pa-tients with these refractory tumors typically have a median overall survival of only 6-33 months. 9,38,56 Modern trials have looked at the possible utility of receptor tyrosine kinase (RTK) inhibitors. Gefitinib, erlotinib, and imatinib, which target platelet-derived growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR), respectively, have generally been ineffective for AM and MM.…”

Section: Chemotherapymentioning

confidence: 99%

An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas

Sun¹,

Hawasli²,

Huang

et al. 2015

FOC

115

View full text Add to dashboard Cite

The management of WHO Grade II “atypical” meningiomas (AMs) and Grade III “malignant” meningiomas (MMs) remains controversial and under-investigated in prospective studies. The roles of surgery, radiation therapy, radiosurgery, and chemotherapy have been incompletely delineated. This has left physicians to decipher how they should treat patients on a case-by-case basis. In this study, the authors review the English-language literature on the management and clinical outcomes associated with AMs and MMs diagnosed using the WHO 2000/2007 grading criteria. Twenty-two studies for AMs and 7 studies for MMs were examined in detail. The authors examined clinical decision points using the literature and concepts from evidence-based medicine. Acknowledging the retrospective nature of the studies concerning AM and MM, the authors did find evidence for the following clinical strategies: 1) maximal safe resection of AM and MM; 2) active surveillance after gross-total resection of AM; 3) adjuvant radiation therapy after subtotal resection of AM, especially in the absence of putative radioresistant features; and 4) adjuvant radiation therapy after resection of MM.

show abstract

“…A variety of cytotoxic chemotherapy agents and targeted molecular therapies have been tried without evidence of efficacy. [2][3][4] The failure to find effective targeted agents is disappointing in light of major recent advances in understanding the biology and molecular pathogenesis of meningiomas. 5,6 In a recent study of the platelet-derived growth factor receptor inhibitor imatinib for recurrent meningiomas, overall median progression-free survival (PFS) was only 2 months, and 6-month PFS (PFS6) was 29%.…”

mentioning

confidence: 99%

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

et al. 2015

View full text Add to dashboard Cite

Objective: A subset of meningiomas recur after surgery and radiation therapy, but no medical therapy for recurrent meningioma has proven effective.Methods: Pasireotide LAR is a long-acting somatostatin analog that may inhibit meningioma growth. This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6 Results: Eighteen patients were accrued in cohort A and 16 in cohort B. Cohort A had median age 59 years, median Karnofsky performance status 80, 17 (94%) had previous radiation therapy, and 11 (61%) showed high octreotide uptake. Cohort B had median age 52 years, median Karnofsky performance status 90, 11 (69%) had previous radiation therapy, and 12 (75%) showed high octreotide uptake. There were no radiographic responses to pasireotide LAR therapy in either cohort. Twelve patients (67%) in cohort A and 13 (81%) in cohort B achieved stable disease. In cohort A, PFS6 was 17% and median PFS 15 weeks (95% confidence interval: 8-20). In cohort B, PFS6 was 50% and median PFS 26 weeks (12-43). Treatment was well tolerated. Octreotide uptake and insulin-like growth factor-1 levels did not predict outcome. Expression of somatostatin receptor 3 predicted favorable PFS and overall survival. Conclusions:Pasireotide LAR has limited activity in recurrent meningiomas. The finding that somatostatin receptor 3 is associated with favorable outcomes warrants further investigation. Classification of evidence:This study provides Class IV evidence that in patients with recurrent or progressive meningioma, pasireotide LAR does not significantly increase the proportion of patients with PFS at 6 months. Neurology ® 2015;84:280-286 GLOSSARY CI 5 confidence interval; IGF-1 5 insulin-like growth factor-1; OS 5 overall survival; PFS 5 progression-free survival; PFS6 5 progression-free survival at 6 months; RANO 5 Response Assessment in Neuro-Oncology; SSTR 5 somatostatin receptor; WHO 5 World Health Organization.Meningiomas are the most common type of benign primary brain tumors in adults.1 Surgical resection is the treatment of choice, and gross total resection is predictive of long-term disease-free survival. Atypical (World Health Organization [WHO] grade 2) and malignant meningiomas (WHO grade 3) confer low rates of long-term survival, especially when gross total resection is not achieved. The typical treatment approach for recurrent disease includes reoperation, frequently accompanied by radiation therapy or stereotactic radiosurgery. These interventions delay a subsequent recurrence but rarely prevent it entirely. When surgery and radiation therapy are no longer

show abstract

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review

Cited by 214 publications

References 47 publications

Increased ⁶⁸Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue

Increased ⁶⁸Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue

An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

Contact Info

Product

Resources

About

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review

Cited by 214 publications

References 47 publications

Increased 68Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue

Increased 68Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue

An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

Contact Info

Product

Resources

About

Increased ⁶⁸Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue

Increased ⁶⁸Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue